Crossmark

Pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects: a prospective observational study in the UAE’s multiethnic population

Crossref DOI link: https://doi.org/10.1186/s40246-025-00753-6

Published Online: 2025-04-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Alqasrawi, Mais N.

Al‑Mahayri, Zeina N.

AlBawa’neh, Areej S.

Khasawneh, Lubna Q.

Dabaghie, Lilas

Altoum, Sahar M.

Hamza, Dana

Misra, Virendra

Ouda, Husam

Aburuz, Salahdein

Al-Maskari, Fatima

AlKaabi, Juma

Patrinos, George P.

Ali, Bassam R. https://orcid.org/0000-0003-1306-6618
Funding

Funding for this research was provided by:

Ministry of Education, United Arab Emirates (grant number 1570604941; UAEU21M139, grant number 1570604941; UAEU21M139, grant number 1570604941; UAEU21M139, grant number 1570604941; UAEU21M139, grant number 1570604941; UAEU21M139, grant number 1570604941; UAEU21M139, grant number 1570604941; UAEU21M139, grant number 1570604941; UAEU21M139, grant number 1570604941; UAEU21M139, grant number 1570604941; UAEU21M139, grant number 1570604941; UAEU21M139, grant number 1570604941; UAEU21M139, grant number 1570604941; UAEU21M139, grant number 1570604941; UAEU21M139)
License Information

Text and Data Mining valid from 2025-04-25

Version of Record valid from 2025-04-25
More Information

Article History

Received: 10 March 2025

Accepted: 12 April 2025

First Online: 25 April 2025

Declarations

:

: This study was conducted in compliance with the Declaration of Helsinki and was approved by the Abu Dhabi Health Research and Technology Ethical Committee (Institutional Review Board - IRB) (Ref. DOH/CVDC/2020/1187). All participants provided written informed consent before enrolment in the study.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below